Skip to main content

Table 2 Diagnostic accuracy of Hemochron™ Signature Elite POCT for edoxaban

From: Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban

Treatment threshold Ideal cut-off Specificity, % Sensitivity, % MP, % LR PPV, % NPV, %
≤30 ng/mL lab-basedcalibratedanti-Xa activity ≤ 30 ng/mL 100.0(91.7–100) 94.0(82.5–98.4) 0.0 100(90.6–100) 94.7(84.5–98.6)
HC-INR ≤ 1.5 98.6(91.2–99.9) 98.0(88.0–99.9) 1.4 68.6(9.8–480.4) 98.0(88.0–99.9) 98.6(91.2–100)
HC-ACT+ ≤ 115 s 97.1(89.1–99.5) 59.2(44.3–72.7) 2.9 20.7(5.2–82.8) 93.5(77.2–98.9) 77.3(66.9–85.2)
HC-ACT-LR ≤ 105 s 97.1(89.1–99.5) 38.3(24.9–53.6) 2.3 13.4(3.3–55.1) 90.0(66.9–98.2) 70.1(59.8–78.8)
HC-aPTT ≤ 68 s 95.7(87.0–98.9) 50.0(35.4–64.6) 4.3 11.5(3.7–36.0) 88.9(69.7–97.1) 73.3(62.8–81.9)
≤50 ng/mL lab-basedcalibratedanti-Xa activity ≤ 50 ng/mL 100(90.6–100) 89.5(77.8–95.6) 0.0 100(91.3–100) 88.7(76.3–95.3)
HC-INR ≤ 2.1 96.8(88.0–99.4) 96.5(86.8–99.4) 3.2 30.4(7.8–119.0) 96.5(86.8–99.4) 96.8(88.0–99.4)
HC-ACT+ ≤ 120 s 95.2(85.8–98.8) 57.1(43.2–70.0) 4.8 12.0(3.9–37.1) 91.4(75.8–97.8) 71.4(60.4–80.5)
HC-ACT-LR ≤ 110 s 95.2(85.8–98.8) 48.1(34.5–62.0) 4.8 10.1(3.2–31.6) 89.7(71.5–97.3) 68.2(57.3–77.5)
HC-aPTT ≤ 68 s 95.2(85.8–98.8) 44.4(31.2–58.5) 4.8 9.3(3.0–29.3) 88.9(69.7–97.1) 66.7(55.9–76.0)
  1. HC-INR, HC-ACT+, HC-ACT-LR, HC-aPTT = Hemochron™ Signature Elite point-of-care test system-based international normalized ratio, activated clotting time, and activated partial thromboplastin time; MP Misprediction percentage; LR Likelihood ratio; PPV Positive predictive value; NPV Negative predictive value. 95%-confidence intervals are reported in brackets wherever applicable